RxDoctor Payments Data

Fawaz Habba, DO

Internal Medicine · Royal Oak, MINPI 1235752759

Payments from drug & device makers

$1,119in general payments, 2019–2025

Across 21 payments — averaging $53.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$266
  • Regeneron Healthcare Solutions, Inc.$238
  • Johnson & Johnson$129
  • Vifor Pharma, Inc.$122
  • Merck$112
  • AbbVie$57
  • plus $193 from 7 others

What the payments were for

  • Food & beverage$1,119100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,119 in reported general payments places this provider in the 75th percentile of 4,567 internal medicine providers in Michigan.

See all internal medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$15,998
Medicare patients
109
Services billed
162

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide11$10,616
Fluticasone Propionate31$346
Pantoprazole Sodium25$292
Atorvastatin Calcium38$289
Metoprolol Succinate16$253
Levothyroxine Sodium19$252
Losartan Potassium23$232
Carvedilol20$219
Omeprazole18$169
Rosuvastatin Calcium18$160
Duloxetine Hcl13$154
Metformin Hcl16$140
Gabapentin16$136
Lisinopril14$130
Simvastatin12$111

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$266$10,61611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,567 internal medicine providers in Michigan.

Other internal medicine in Royal Oak

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →